Literature DB >> 27246475

[Can circulating tumor cells be a predicative biomarker?].

G Theil1, P Fornara2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27246475     DOI： 10.1007/s00120-016-0129-y

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  5 in total

Review 1.  Biomarker development in the context of urologic cancers.

Authors:  Gary J Kelloff; Caroline C Sigman; Howard I Scher
Journal:  Urol Oncol       Date:  2015-03-05       Impact factor: 3.498

2.  Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Authors:  M Nakazawa; C Lu; Y Chen; C J Paller; M A Carducci; M A Eisenberger; J Luo; E S Antonarakis
Journal:  Ann Oncol       Date:  2015-06-27       Impact factor: 32.976

Review 3.  AR-V7 and prostate cancer: The watershed for treatment selection?

Authors:  Chiara Ciccarese; Matteo Santoni; Matteo Brunelli; Sebastiano Buti; Alessandra Modena; Massimo Nabissi; Walter Artibani; Guido Martignoni; Rodolfo Montironi; Giampaolo Tortora; Francesco Massari
Journal:  Cancer Treat Rev       Date:  2015-12-18       Impact factor: 12.111

4.  Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Authors:  Wendy Onstenk; Anieta M Sieuwerts; Jaco Kraan; Mai Van; Annemieke J M Nieuweboer; Ron H J Mathijssen; Paul Hamberg; Hielke J Meulenbeld; Bram De Laere; Luc Y Dirix; Robert J van Soest; Martijn P Lolkema; John W M Martens; Wytske M van Weerden; Guido W Jenster; John A Foekens; Ronald de Wit; Stefan Sleijfer
Journal:  Eur Urol       Date:  2015-07-15       Impact factor: 20.096

5.  Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer.

Authors:  Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.